Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 9, 2018March 9, 2018

FDA OKs First At-home Genetic Test for Breast Cancer Risk, but Focus Is Limited

News

U.S. regulators have approved the first genetic test a woman can take at home to check her risk of developing breast cancer — but its focus is narrow, essentially applying only ... Read more

March 2, 2018March 2, 2018

EMA’s CHMP Issues Negative Opinion of Neratinib as Added Therapy in Early Stage HER2-positive Breast Cancer

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion of neratinib as an extended adjuvant treatment of early stage, HER-2 positive breast cancer. ... Read more

February 28, 2018February 28, 2018

Verzenio Approved for Postmenopausal Women with HR+, HER2- Advanced Breast Cancer

News

The U.S. Food and Drug Administration approved Eli Lilly‘s Verzenio (abemaciclib) in combination with an aromatase inhibitor as an initial treatment for postmenopausal women with advanced breast cancer. Verzenio is for breast ... Read more

February 23, 2018February 23, 2018

Imaging System May Help Identify Breast Cancer Patients Likely to Respond to Chemotherapy

News

A new imaging system under development uses red and near-infrared light to identify breast cancer patients who are likely to respond to chemotherapy, possibly as early as two weeks after ... Read more

February 5, 2018February 5, 2018

Breast Cancer Treatments May Increase Heart Disease Risk, American Heart Association Says

News

Breast cancer patients may experience a higher risk for cardiovascular disease, including heart failure, according to a recent scientific statement published by the American Heart Association. When making decisions about ... Read more

January 29, 2018January 29, 2018

Gene Therapy Could Prevent Radiotherapy Side Effects, Improve Breast Reconstruction, Study Suggests

News

A new virus-based gene therapy could protect healthy tissue from the effects of radiotherapy and improve breast reconstruction surgery, a study with lab rats suggests. The therapy delivers copies of stress-limiting ... Read more

January 17, 2018

Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer

News

An upcoming Phase 1b/2 trial will evaluate Syndax Pharmaceuticals‘ investigational therapy entinostat in combination with Genentech‘s Tecentriq (atezolizumab) in women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative ... Read more

January 10, 2018

Kisqali Granted Breakthrough Therapy Status to Treat Breast Cancer in Premenopausal Women

News

The U.S. Food and Drug Administration (FDA) has granted Kisqali (ribociclib) Breakthrough Therapy designation for the treatment of premenopausal women with HR-positive, HER2-negative advanced breast cancer who have not received prior endocrine ... Read more

January 5, 2018

Biannual MRI Better Than Annual Mammogram at Detecting Breast Cancer in High-risk Women, Study Finds

News

For young women with high genetic risk for breast cancer, intensive surveillance and examination by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) every six months is more effective for timely detection of ... Read more

October 27, 2017

LiPlaCis Shows Promise in Phase 2 Part of Trial Dealing with Hard to Treat Breast Cancer

News

Three of five patients with breast cancer that had spread to other organs responded to Oncology Ventures’ LiPlaCis or had their disease become stable with it, according to early results of the ... Read more